Strategic partnerships Geneoscopy collaborates with leading universities and biopharmaceutical companies to develop diagnostic tests across GI diseases, indicating potential for co-development opportunities, clinical partnerships, and licensing discussions with healthcare and pharma players.

FDA approved core ColoSense is FDA-approved for colorectal cancer and advanced adenomas screening in average-risk individuals over 45, presenting a scalable entry point for hospital systems, payer conversations, and primary care networks seeking approved GI screening solutions.

Recent funding Significant Series C funding of 105 million alongside executive leadership expansion signals rapid growth and readiness to scale sales teams, clinical deployments, and commercial partnerships across broader GI diagnostics markets.

Clinical integration Integration with Bio-Rad’s QXDx ddPCR platform and ongoing litigation with Exact Sciences suggest a competitive landscape and opportunity to position ColoSense as interoperable and differentiated in molecular diagnostics with strong technical and funding backing.

Growth traction revenue range of 25 to 50 million and a headcount up to 200+ reflect a mid-sized biotech with increasing market adoption; ideal for targeting mid-market health systems, ambulatory networks, and regional labs seeking scalable GI screening solutions.